carisoprodol (Rx)

Brand and Other Names:Soma
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet: Schedule IV

  • 250mg
  • 350mg

Musculoskeletal Conditions

250-350 mg q8hr and HS; not to exceed 2-3 weeks; taper slowly (over 14 days) in patients with history of long term use to avoid withdrawal symptoms, including insomnia, anxiety, or irritability

Dosing Modifications

Renal impairment: Caution; not studied

Hepatic impairment: Caution; not studied

Dosage Forms & Strengths

tablet: Schedule IV

  • 250mg
  • 350mg

Musculoskeletal Conditions

<16 years: Not recommended

>16 years: 250-350 mg q8hr and HS; not to exceed 2-3 weeks; taper slowly (over 14 days) in patients with history of long term use to avoid withdrawal symptoms, including insomnia, anxiety, or irritability

Not drug of choice in elderly, owing to risk of orthostatic hypotension and CNS depression

Next:

Interactions

Interaction Checker

and carisoprodol

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (9)

              • apalutamide

                apalutamide will decrease the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP2C19 inducer, with drugs that are CYP2C19 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered.

              • benzhydrocodone/acetaminophen

                benzhydrocodone/acetaminophen, carisoprodol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • calcium/magnesium/potassium/sodium oxybates

                carisoprodol, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • hydrocodone

                hydrocodone, carisoprodol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • lonafarnib

                lonafarnib will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Lonafarnib may increase the AUC and peak concentration of CYP2C19 substrates. If coadministration unavoidable, monitor for adverse reactions and reduce the CYP2C19 substrate dose in accordance with its approved product labeling.

              • metoclopramide intranasal

                carisoprodol, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.

              • selinexor

                selinexor, carisoprodol. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.

              • sodium oxybate

                carisoprodol, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • sufentanil SL

                sufentanil SL, carisoprodol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              Monitor Closely (160)

              • abobotulinumtoxinA

                carisoprodol increases effects of abobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.

              • alfentanil

                carisoprodol and alfentanil both increase sedation. Use Caution/Monitor.

              • alprazolam

                alprazolam and carisoprodol both increase sedation. Use Caution/Monitor.

              • amitriptyline

                carisoprodol and amitriptyline both increase sedation. Use Caution/Monitor.

              • amobarbital

                amobarbital and carisoprodol both increase sedation. Use Caution/Monitor.

              • amoxapine

                carisoprodol and amoxapine both increase sedation. Use Caution/Monitor.

              • apomorphine

                carisoprodol and apomorphine both increase sedation. Use Caution/Monitor.

              • aripiprazole

                carisoprodol and aripiprazole both increase sedation. Use Caution/Monitor.

              • azelastine

                azelastine and carisoprodol both increase sedation. Use Caution/Monitor.

              • baclofen

                baclofen and carisoprodol both increase sedation. Use Caution/Monitor.

              • belladonna and opium

                carisoprodol and belladonna and opium both increase sedation. Use Caution/Monitor.

              • benperidol

                carisoprodol and benperidol both increase sedation. Use Caution/Monitor.

              • benzphetamine

                carisoprodol increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • brexanolone

                brexanolone, carisoprodol. Either increases toxicity of the other by sedation. Use Caution/Monitor.

              • brompheniramine

                brompheniramine and carisoprodol both increase sedation. Use Caution/Monitor.

              • buprenorphine

                carisoprodol and buprenorphine both increase sedation. Use Caution/Monitor.

              • buprenorphine buccal

                carisoprodol and buprenorphine buccal both increase sedation. Use Caution/Monitor.

              • buprenorphine, long-acting injection

                buprenorphine, long-acting injection increases effects of carisoprodol by Other (see comment). Modify Therapy/Monitor Closely. Comment: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and increase risk for respiratory depression. Monitor for signs of respiratory depression that may be greater than otherwise expected and decrease muscle relaxant dosage as necessary.

              • butabarbital

                butabarbital and carisoprodol both increase sedation. Use Caution/Monitor.

              • butalbital

                butalbital and carisoprodol both increase sedation. Use Caution/Monitor.

              • butorphanol

                carisoprodol and butorphanol both increase sedation. Use Caution/Monitor.

              • cannabidiol

                cannabidiol will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol.

              • carbinoxamine

                carbinoxamine and carisoprodol both increase sedation. Use Caution/Monitor.

              • cenobamate

                cenobamate will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider a dose reduction of CYP2C19 substrates, as clinically appropriate, when used concomitantly with cenobamate.

                cenobamate, carisoprodol. Either increases effects of the other by sedation. Use Caution/Monitor.

              • chloral hydrate

                chloral hydrate and carisoprodol both increase sedation. Use Caution/Monitor.

              • chlordiazepoxide

                chlordiazepoxide and carisoprodol both increase sedation. Use Caution/Monitor.

              • chlorpheniramine

                chlorpheniramine and carisoprodol both increase sedation. Use Caution/Monitor.

              • chlorpromazine

                carisoprodol and chlorpromazine both increase sedation. Use Caution/Monitor.

              • cinnarizine

                cinnarizine and carisoprodol both increase sedation. Use Caution/Monitor.

              • clemastine

                clemastine and carisoprodol both increase sedation. Use Caution/Monitor.

              • clobazam

                carisoprodol, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).

              • clomipramine

                carisoprodol and clomipramine both increase sedation. Use Caution/Monitor.

              • clonazepam

                clonazepam and carisoprodol both increase sedation. Use Caution/Monitor.

              • clorazepate

                clorazepate and carisoprodol both increase sedation. Use Caution/Monitor.

              • clozapine

                carisoprodol and clozapine both increase sedation. Use Caution/Monitor.

              • codeine

                carisoprodol and codeine both increase sedation. Use Caution/Monitor.

              • cyclizine

                cyclizine and carisoprodol both increase sedation. Use Caution/Monitor.

              • cyclobenzaprine

                carisoprodol and cyclobenzaprine both increase sedation. Use Caution/Monitor.

              • cyproheptadine

                cyproheptadine and carisoprodol both increase sedation. Use Caution/Monitor.

              • dantrolene

                carisoprodol and dantrolene both increase sedation. Use Caution/Monitor.

              • desipramine

                carisoprodol and desipramine both increase sedation. Use Caution/Monitor.

              • dexchlorpheniramine

                dexchlorpheniramine and carisoprodol both increase sedation. Use Caution/Monitor.

              • dexfenfluramine

                carisoprodol increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dexmedetomidine

                dexmedetomidine and carisoprodol both increase sedation. Use Caution/Monitor.

              • dextromoramide

                carisoprodol and dextromoramide both increase sedation. Use Caution/Monitor.

              • diamorphine

                carisoprodol and diamorphine both increase sedation. Use Caution/Monitor.

              • diazepam

                diazepam and carisoprodol both increase sedation. Use Caution/Monitor.

              • diazepam intranasal

                diazepam intranasal, carisoprodol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.

              • difenoxin hcl

                carisoprodol and difenoxin hcl both increase sedation. Use Caution/Monitor.

              • dimenhydrinate

                dimenhydrinate and carisoprodol both increase sedation. Use Caution/Monitor.

              • diphenhydramine

                diphenhydramine and carisoprodol both increase sedation. Use Caution/Monitor.

              • diphenoxylate hcl

                carisoprodol and diphenoxylate hcl both increase sedation. Use Caution/Monitor.

              • dipipanone

                carisoprodol and dipipanone both increase sedation. Use Caution/Monitor.

              • dopexamine

                carisoprodol increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dosulepin

                carisoprodol and dosulepin both increase sedation. Use Caution/Monitor.

              • doxepin

                carisoprodol and doxepin both increase sedation. Use Caution/Monitor.

              • doxylamine

                doxylamine and carisoprodol both increase sedation. Use Caution/Monitor.

              • droperidol

                carisoprodol and droperidol both increase sedation. Use Caution/Monitor.

              • elagolix

                elagolix will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak CYP2C19 inhibitor. Caution with sensitive CYP2C19 substrates.

              • esketamine intranasal

                esketamine intranasal, carisoprodol. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.

              • eslicarbazepine acetate

                eslicarbazepine acetate will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.

              • estazolam

                estazolam and carisoprodol both increase sedation. Use Caution/Monitor.

              • ethanol

                carisoprodol and ethanol both increase sedation. Use Caution/Monitor.

              • etomidate

                etomidate and carisoprodol both increase sedation. Use Caution/Monitor.

              • fedratinib

                fedratinib will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2C19 substrates as necessary.

              • fenfluramine

                carisoprodol increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • fexinidazole

                fexinidazole will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.

              • fluphenazine

                carisoprodol and fluphenazine both increase sedation. Use Caution/Monitor.

              • flurazepam

                flurazepam and carisoprodol both increase sedation. Use Caution/Monitor.

              • haloperidol

                carisoprodol and haloperidol both increase sedation. Use Caution/Monitor.

              • hydromorphone

                carisoprodol and hydromorphone both increase sedation. Use Caution/Monitor.

              • hydroxyzine

                hydroxyzine and carisoprodol both increase sedation. Use Caution/Monitor.

              • iloperidone

                carisoprodol and iloperidone both increase sedation. Use Caution/Monitor.

              • imipramine

                carisoprodol and imipramine both increase sedation. Use Caution/Monitor.

              • incobotulinumtoxinA

                carisoprodol, incobotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.

              • ketamine

                ketamine and carisoprodol both increase sedation. Use Caution/Monitor.

              • ketotifen, ophthalmic

                carisoprodol and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.

              • lasmiditan

                lasmiditan, carisoprodol. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.

              • lemborexant

                lemborexant, carisoprodol. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.

              • levorphanol

                carisoprodol and levorphanol both increase sedation. Use Caution/Monitor.

              • lofepramine

                carisoprodol and lofepramine both increase sedation. Use Caution/Monitor.

              • lofexidine

                carisoprodol and lofexidine both increase sedation. Use Caution/Monitor.

              • loprazolam

                loprazolam and carisoprodol both increase sedation. Use Caution/Monitor.

              • lorazepam

                lorazepam and carisoprodol both increase sedation. Use Caution/Monitor.

              • lormetazepam

                lormetazepam and carisoprodol both increase sedation. Use Caution/Monitor.

              • loxapine

                carisoprodol and loxapine both increase sedation. Use Caution/Monitor.

              • loxapine inhaled

                carisoprodol and loxapine inhaled both increase sedation. Use Caution/Monitor.

              • lumacaftor/ivacaftor

                lumacaftor/ivacaftor, carisoprodol. affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C19 substrates. .

              • lurasidone

                lurasidone, carisoprodol. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.

              • maprotiline

                carisoprodol and maprotiline both increase sedation. Use Caution/Monitor.

              • marijuana

                carisoprodol and marijuana both increase sedation. Use Caution/Monitor.

              • melatonin

                carisoprodol and melatonin both increase sedation. Use Caution/Monitor.

              • meperidine

                carisoprodol and meperidine both increase sedation. Use Caution/Monitor.

              • meprobamate

                carisoprodol and meprobamate both increase sedation. Use Caution/Monitor.

              • metaxalone

                carisoprodol and metaxalone both increase sedation. Use Caution/Monitor.

              • methadone

                carisoprodol and methadone both increase sedation. Use Caution/Monitor.

              • methocarbamol

                carisoprodol and methocarbamol both increase sedation. Use Caution/Monitor.

              • methylenedioxymethamphetamine

                carisoprodol increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • midazolam

                midazolam and carisoprodol both increase sedation. Use Caution/Monitor.

              • midazolam intranasal

                midazolam intranasal, carisoprodol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.

              • mirtazapine

                carisoprodol and mirtazapine both increase sedation. Use Caution/Monitor.

              • morphine

                carisoprodol and morphine both increase sedation. Use Caution/Monitor.

              • motherwort

                carisoprodol and motherwort both increase sedation. Use Caution/Monitor.

              • moxonidine

                carisoprodol and moxonidine both increase sedation. Use Caution/Monitor.

              • nabilone

                carisoprodol and nabilone both increase sedation. Use Caution/Monitor.

              • nalbuphine

                carisoprodol and nalbuphine both increase sedation. Use Caution/Monitor.

              • nortriptyline

                carisoprodol and nortriptyline both increase sedation. Use Caution/Monitor.

              • olanzapine

                carisoprodol and olanzapine both increase sedation. Use Caution/Monitor.

              • oliceridine

                oliceridine, carisoprodol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

                carisoprodol increases toxicity of oliceridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.

              • ombitasvir/paritaprevir/ritonavir & dasabuvir

                ombitasvir/paritaprevir/ritonavir & dasabuvir decreases effects of carisoprodol by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Increase dose if clinically indicated.

              • opium tincture

                carisoprodol and opium tincture both increase sedation. Use Caution/Monitor.

              • orphenadrine

                carisoprodol and orphenadrine both increase sedation. Use Caution/Monitor.

              • oxazepam

                oxazepam and carisoprodol both increase sedation. Use Caution/Monitor.

              • oxycodone

                carisoprodol and oxycodone both increase sedation. Use Caution/Monitor.

              • oxymorphone

                carisoprodol and oxymorphone both increase sedation. Use Caution/Monitor.

              • paliperidone

                carisoprodol and paliperidone both increase sedation. Use Caution/Monitor.

              • papaveretum

                carisoprodol and papaveretum both increase sedation. Use Caution/Monitor.

              • papaverine

                carisoprodol and papaverine both increase sedation. Use Caution/Monitor.

              • pentazocine

                carisoprodol and pentazocine both increase sedation. Use Caution/Monitor.

              • pentobarbital

                pentobarbital and carisoprodol both increase sedation. Use Caution/Monitor.

              • perphenazine

                carisoprodol and perphenazine both increase sedation. Use Caution/Monitor.

              • phenobarbital

                phenobarbital and carisoprodol both increase sedation. Use Caution/Monitor.

              • phenylephrine PO

                carisoprodol increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

              • pholcodine

                carisoprodol and pholcodine both increase sedation. Use Caution/Monitor.

              • pimozide

                carisoprodol and pimozide both increase sedation. Use Caution/Monitor.

              • prabotulinumtoxinA

                carisoprodol increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.

              • primidone

                primidone and carisoprodol both increase sedation. Use Caution/Monitor.

              • prochlorperazine

                carisoprodol and prochlorperazine both increase sedation. Use Caution/Monitor.

              • promethazine

                promethazine and carisoprodol both increase sedation. Use Caution/Monitor.

              • propofol

                propofol and carisoprodol both increase sedation. Use Caution/Monitor.

              • propylhexedrine

                carisoprodol increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • protriptyline

                carisoprodol and protriptyline both increase sedation. Use Caution/Monitor.

              • quazepam

                quazepam and carisoprodol both increase sedation. Use Caution/Monitor.

              • quetiapine

                carisoprodol and quetiapine both increase sedation. Use Caution/Monitor.

              • ramelteon

                carisoprodol and ramelteon both increase sedation. Use Caution/Monitor.

              • remimazolam

                remimazolam, carisoprodol. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.

              • risperidone

                carisoprodol and risperidone both increase sedation. Use Caution/Monitor.

              • rucaparib

                rucaparib will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP2C19 substrates, if clinically indicated.

              • scullcap

                carisoprodol and scullcap both increase sedation. Use Caution/Monitor.

              • secobarbital

                secobarbital and carisoprodol both increase sedation. Use Caution/Monitor.

              • shepherd's purse

                carisoprodol and shepherd's purse both increase sedation. Use Caution/Monitor.

              • stiripentol

                stiripentol will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of CYP2C19 substrates, if adverse reactions are experienced when administered concomitantly with stiripentol.

                stiripentol, carisoprodol. Either increases effects of the other by sedation. Use Caution/Monitor. Concurrent use of medications with CNS depressant effects together with thalidomide should be avoided due to the risk for additive sedative effects.

              • sufentanil

                carisoprodol and sufentanil both increase sedation. Use Caution/Monitor.

              • tapentadol

                carisoprodol and tapentadol both increase sedation. Use Caution/Monitor.

              • tecovirimat

                tecovirimat will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Tecovirimat is a weak inhibitor of CYP2C8 and CYP2C19. Monitor for adverse effects if coadministered with sensitive substrates of these enzymes.

              • temazepam

                temazepam and carisoprodol both increase sedation. Use Caution/Monitor.

              • thioridazine

                carisoprodol and thioridazine both increase sedation. Use Caution/Monitor.

              • thiothixene

                carisoprodol and thiothixene both increase sedation. Use Caution/Monitor.

              • topiramate

                carisoprodol and topiramate both increase sedation. Modify Therapy/Monitor Closely.

              • tramadol

                carisoprodol and tramadol both increase sedation. Use Caution/Monitor.

              • trazodone

                carisoprodol and trazodone both increase sedation. Use Caution/Monitor.

              • triazolam

                triazolam and carisoprodol both increase sedation. Use Caution/Monitor.

              • triclabendazole

                triclabendazole will increase the level or effect of carisoprodol by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

              • triclofos

                triclofos and carisoprodol both increase sedation. Use Caution/Monitor.

              • trifluoperazine

                carisoprodol and trifluoperazine both increase sedation. Use Caution/Monitor.

              • trimipramine

                carisoprodol and trimipramine both increase sedation. Use Caution/Monitor.

              • xylometazoline

                carisoprodol increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ziconotide

                carisoprodol and ziconotide both increase sedation. Use Caution/Monitor.

              • ziprasidone

                carisoprodol and ziprasidone both increase sedation. Use Caution/Monitor.

              • zotepine

                carisoprodol and zotepine both increase sedation. Use Caution/Monitor.

              Minor (2)

              • eucalyptus

                carisoprodol and eucalyptus both increase sedation. Minor/Significance Unknown.

              • sage

                carisoprodol and sage both increase sedation. Minor/Significance Unknown.

              Previous
              Next:

              Adverse Effects

              >10%

              Drowsiness (13-17%)

              1-10%

              Dizziness (7-8%)

              Headache (3-5%)

              Frequency Not Defined

              Orthostatic hypotension

              Syncope

              Tachycardia

              Agitation

              Irritability

              Depression

              Allergic/idiosyncratic reactions (pruritus, rash, dizziness, etc)

              Epigastric distress

              N/V

              Facial flushing

              Weakness

              Previous
              Next:

              Warnings

              Contraindications

              Hypersensitivity to carisoprodol, meprobamate, mebutamate, tybamate

              History of acute intermittent porphyria

              Cautions

              Caution in hepatic/renal impairment

              May cause CNS depression; use caution when performing tasks which require mental alertness (eg, operating heavy machinery); sedating effects potentiated when used with other CNS-depressant drugs or ethanol

              Severe weakness may occur

              Seizures reported with its use in patients with or without seizure history

              Risk of allergic reactions

              Use caution in patients with history of drug abuse or acute alcoholism; drug dependency may occur and withdrawal symptoms experienced with abrupt cessation, especially with long-term use; limit use to 2-3 weeks

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy

              Data over many decades of use of drug in pregnancy have not identified drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes; data on meprobamate, the primary metabolite of carisoprodol, do not show consistent association between maternal use and increased risk of major birth defects

              Animal data

              • In a published animal reproduction study, pregnant mice administered carisoprodol orally at 2.6- and 4.1-times maximum recommended human dose of 1400 mg per day [350 mg QID] based on body surface area comparison) from gestation through weaning resulted in reduced fetal weights, postnatal weight gain, and postnatal survival

              Lactation

              Data from published literature report that carisoprodol and its metabolite, meprobamate, are present in breastmilk; there are no data on effect on milk production; there is one report of sedation in an infant who was breastfed by a mother taking carisoprodol; because there have been no consistent reports of adverse events in breastfed infants over decades of use, the developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant or from underlying maternal condition; infants exposed to drug through breast milk should be monitored for sedation

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Not clearly known; may block interneural activity and depress polysynaptic neuron transmission

              Absorption

              Onset: 30 min

              Duration: 4-6 hr

              Peak plasma time: 1.5-2 hr

              Metabolism

              Metabolized by liver microsomal enzymes (CYP2C19)

              Elimination

              Half-life: 2 hr; meprobamate (8 hr)

              Dialyzable: Yes (HD, PD)

              Excretion: Urine

              Previous
              Next:

              Images

              BRAND FORM. UNIT PRICE PILL IMAGE
              carisoprodol oral
              -
              350 mg tablet
              carisoprodol oral
              -
              350 mg tablet
              carisoprodol oral
              -
              350 mg tablet
              carisoprodol oral
              -
              350 mg tablet
              carisoprodol oral
              -
              350 mg tablet
              carisoprodol oral
              -
              350 mg tablet
              carisoprodol oral
              -
              350 mg tablet
              carisoprodol oral
              -
              250 mg tablet
              carisoprodol oral
              -
              250 mg tablet
              carisoprodol oral
              -
              250 mg tablet
              carisoprodol oral
              -
              250 mg tablet
              carisoprodol oral
              -
              350 mg tablet
              Soma oral
              -
              350 mg tablet
              Soma oral
              -
              250 mg tablet
              Soma oral
              -
              350 mg tablet
              Vanadom oral
              -
              350 mg tablet

              Copyright © 2010 First DataBank, Inc.

              Previous
              Next:

              Patient Handout

              Patient Education
              carisoprodol oral

              CARISOPRODOL - ORAL

              (kar-iss-oh-PRO-dole)

              COMMON BRAND NAME(S): Soma

              USES: Carisoprodol is used short-term to treat muscle pain and discomfort. It is usually used along with rest, physical therapy, and other treatments. It works by helping to relax the muscles.

              HOW TO USE: Take this medication by mouth with or without food as directed by your doctor. Do not increase your dose or use this drug more often or for longer than prescribed. Your condition will not improve any faster, and your risk of side effects will increase.The dosage is based on your medical condition and response to treatment. This medication should only be used short-term (for 3 weeks or less) unless directed by your doctor.If you suddenly stop using this medication, you may have withdrawal symptoms (such as stomach cramps, trouble sleeping, headache, nausea). To help prevent withdrawal, your doctor may lower your dose slowly. Withdrawal is more likely if you have used carisoprodol for a long time or in high doses. Tell your doctor or pharmacist right away if you have withdrawal.Though it helps many people, this medication may sometimes cause addiction. This risk may be higher if you have a substance use disorder (such as overuse of or addiction to drugs/alcohol). Take this medication exactly as prescribed to lower the risk of addiction. Ask your doctor or pharmacist for more details.Tell your doctor if your condition persists after 2 to 3 weeks or if it worsens.

              SIDE EFFECTS: Dizziness, drowsiness, or headache may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: confusion.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

              PRECAUTIONS: Before taking carisoprodol, tell your doctor or pharmacist if you are allergic to it; or to meprobamate, tybamate, or mebutamate; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: a certain blood disorder (acute intermittent porphyria), kidney disease, liver disease, seizure, personal or family history of a substance use disorder (such as overuse of or addiction to drugs/alcohol).This drug may make you dizzy or drowsy. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Avoid alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug, especially drowsiness, or confusion. These side effects can increase the risk of falling.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.This medication passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breast-feeding.

              DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Tell your doctor or pharmacist if you are taking other products that cause drowsiness such as opioid pain or cough relievers (such as codeine, hydrocodone), alcohol, marijuana (cannabis), drugs for sleep or anxiety (such as alprazolam, lorazepam, zolpidem), other muscle relaxants (such as cyclobenzaprine, methocarbamol), or antihistamines (such as cetirizine, diphenhydramine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.

              OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe drowsiness/dizziness, seizures, slow/shallow breathing, mental/mood changes (such as confusion, hallucinations), inability to move your legs/arms, shaky/unsteady movement, vision changes (such as blurred vision).

              NOTES: Do not share this medication with others. Sharing it is against the law.This medication has been prescribed for your current condition only. Do not use it later for another condition unless your doctor directs you to do so. A different medication may be necessary in that case.

              MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.

              STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

              Information last revised August 2021. Copyright(c) 2021 First Databank, Inc.

              IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.